Webinar: ‘Updates of the QT/QTc evaluation guidance: industry and expert perspectives’
Thursday, January 25, 2024 from 3:00 PM to 4:00 PM
Zoom Meeting
The regulatory landscape for assessing the proarrhythmic risk during drug development is changing. The recent update considers an integrated approach of the ICH14 and S7B guidances. Under certain conditions, this brings new insights for the industry, offering the use of non-clinical data during clinical development to overcome the limitations when a high clinical exposure scenario cannot be assessed.
The speakers will provide their perspective of this regulatory update and its impact during drug development.
Speakers:
-
- Dr. Philippe Grosjean (PhD) – ECG Subject Matter Expert – Sanofi R&D, France
- Dr. Pierre Maison-Blanche (MD) – Cardiac Safety Expert – Public Hospitals of Paris (AP-HP), France
Prices
| Ticket type | Price |
|---|---|
| Webinar 25/01 future member ticket | Free |
| Webinar 25/01 member ticket | Free |
| Webinar 25/01 non-member ticket | € 30.00 |
21% VAT will be applicable on the ticket prices
This event is organised by 2Mpact for AFPT – Club Phase 1.You need to create your account on this website in order to be able to register for this event. Invoices will be sent out by 2Mpact.
Free participation is possible for:
- current members of AFPT – Club Phase 1 (Association Française de Pharmacologie Translationnelle)
- future members of AFPT – Club Phase 1: after this webinar, you will be contacted by AFPT – Club Phase 1 to join as a member for 2024, so you can access other webinars in 2024 for free.
